(R)-2-Amino-6-Propionamido-4,5,6,7-Tetrahydrobenzothiazole

When deployed as a chiral resolving agent for 2-arylpropionic acid racemates, (R)-2-Amino-6-propionamido-4,5,6,7-tetrahydrobenzothiazole forms diastereomeric salt pairs whose solubility differential in polar aprotic–protic blended solvents enables industrial-scale crystallisation-based enantioseparation. The propionamide substituent at the C-6 position introduces a hydrogen-bonding acceptor that engages the carboxylic acid moiety of the target substrate, while the tetrahydrobenzothiazole ring provides π-stacking surfaces that enhance crystal lattice enthalpy differentiation between the two diastereomeric salts. In dedicated manufacturing suites compliant with ICH Q7 and 21 CFR Part 211, the racemate is co-dissolved with 0.50–0.55 molar equivalents of the resolving agent in a mixture of methyl isobutyl ketone and 3–5% (v/v) deionised water at 60–65 °C under nitrogen blanketing. The batch is transferred to a draft-tube baffled (DTB) crystalliser with a programmed cooling ramp of 0.15 °C/min through the metastable zone width, a rate empirically validated against focused beam reflectance measurement (FBRM) chord-length trends to suppress secondary nucleation and avoid occluded mother liquor that would depress enantiomeric excess. Seed crystals of the target (S)-enantiomer salt (prepared in a prior micronisation step) are introduced at 48–50 °C at a loading of 0.1 wt% relative to the theoretical salt yield. After a 12‑hour isothermal hold at 25 °C, the crystalline product is spun on a peeler centrifuge, washed with pre-chilled methyl isobutyl ketone, and acidified with 2 M hydrochloric acid to liberate the (S)-enantiomer acid, which is extracted into methyl tert‑butyl ether and polished through a wiped-film evaporator at ≤30 mbar. Residual (R)-resolving agent recovered from the mother liquor is racemised or recycled after counter-current extraction to maintain process economics. Regulatory compliance with ICH Q3C residual solvent limits requires headspace GC–FID monitoring for methyl isobutyl ketone below 25 ppm in the final isolate; heavy metal control is managed through inductively coupled plasma–mass spectrometry per USP ⟨232⟩/⟨233⟩. The output material—typically high-purity (S)-naproxen or (S)-ibuprofen—achieves enantiomeric excess ≥ 99.5% (chiral HPLC, Chiralpak IG‑3, n‑hexane/ethanol/trifluoroacetic acid) and polymorphic identity consistent with Form I by powder X‑ray diffraction reference pattern, enabling direct compaction into finished solid dosage analgesics under ICH Q6A decision trees.

What Dictates the Molar Equivalency Window in Diastereomeric Salt Resolution of 2‑Arylpropionate Racemates?

Deviations from the stoichiometric window of 0.50–0.55 molar equivalents in the diastereomeric salt resolution step alter the crystal harvesting profile in ways that are often misinterpreted as solvent effect artefacts. At a resolving-agent loading of 0.48 eq, only partial neutralisation of the target (S)-enantiomer occurs, leaving unreacted free acid in the mother liquor that co‑precipitates upon acidification and depresses the overall optical purity of the liberated (S)-acid to below 97% ee. At loadings exceeding 0.60 eq, the excess (R)-amine, which is itself poorly soluble in the cold crystallisation solvent, crystallises as a discrete phase or co‑crystallises as mixed-salt inclusion aggregates that resist redissolution during the washing step, elevating nitrogen content in the final active pharmaceutical ingredient, a parameter flagged by elemental analysis for CHN during batch release. Process analytical technology (PAT) implementation in pilot campaigns at the 500‑L scale (Mettler‑Toledo ReactIR 45m) demonstrated that the amine carbonyl stretching band at 1652 cm⁻¹, corresponding to the propionamide donor, shifts by 8 cm⁻¹ upon salt formation; inline mid‑IR tracking of this band against a pre‑validated partial least squares model enables closed‑loop feedback control of titrant addition to within ±0.02 eq of the setpoint. The downstream production sequence utilises a Hastelloy C‑22 reactor train compliant with pressure vessel code ISO 16528, and final crystallisation under continuous oscillatory baffled flow (COBR) configuration reduces batch cycle time by 40% versus the stationary DTB vessel while maintaining coefficient of variation in crystal size distribution below 15%. The terminal manufactured goods span the non‑steroidal anti‑inflammatory drug class: (S)-naproxen (USP monograph), (S)-ibuprofen lysinate for parenteral formulation, and (S)-flurbiprofen for ophthalmic surgery, each supported by comparator dissolution profiles against the innovator reference listed drug under FDA SUPAC‑MR guidance.

Chiral derivatisation of non‑chromophoric monomeric substrates, including amino acids and their N‑acetyl derivatives, for enantiomeric excess monitoring in continuous‑flow peptide synthesis employs this tetrahydrobenzothiazole aminoamide as a pre‑column derivatising agent. The reagent is activated in situ with 1.2–1.5 molar equivalents of N,N'‑dicyclohexylcarbodiimide and 0.2 equivalents of 1‑hydroxybenzotriazole in anhydrous dimethylformamide at 0–5 °C, then combined with the analyte in a micro‑reactor fitted with a residence‑time‑loop calibration against an internal standard of l‑phenylalanine‑d₈. After quenching with dilute bicarbonate, the resultant diastereomeric amides are resolved on a Chiralpak AD‑H column (250 × 4.6 mm, 5 µm) with a mobile phase of n‑hexane/2‑propanol/diethylamine (85:15:0.1) at 1.0 mL/min. The limit of detection for the minor enantiomer reaches 0.03% in a 20 µL injection, satisfying the quantitation limit guidelines of ICH Q2(R2) for impurity method validation. Facility operations for derivatisation kit production comply with ISO 13485 where the kit is packaged as a reagent‑solvent‑column consumable set, and the linearity range is re‑validated every 6 months via a five‑level calibration protocol across 0.05%–5.0% (w/w) of the undesired enantiomer. The end‑use artifacts are validated certificates of analysis reporting stereochemical purity of peptide building blocks destined for glucagon‑like peptide‑1 receptor agonist solid‑phase synthesis, linking directly to the in‑process control strategy demanded by ICH Q11 for chemical development.

Process‑scale synthesis of (R)-pramipexole dihydrochloride for compendial impurity profiling relies on the catalytic hydrogenolysis of the propionamide side chain of (R)-2-Amino-6-propionamido-4,5,6,7-tetrahydrobenzothiazole under strictly anhydrous conditions to prevent retro‑Michael fragmentation of the tetrahydrothiazole ring. The substrate is dissolved in tetrahydrofuran at 0.8–1.0 M and transferred to a jacketed autoclave equipped with a gas‑entrainment impeller, where Raney‑nickel (Grade 4200, 5 wt% loading relative to substrate) is pre‑activated by washing with deionised water to remove fines and stored under argon. Ammonia gas is sparged at 2 bar for 10 minutes to saturate the liquor and suppress secondary amine formation, then hydrogen is introduced at 35 bar and the mixture is heated to 80 °C with a ramp rate of 1.5 °C/min until hydrogen uptake ceases (monitored via a Brooks mass flow controller). The crude diamine solution is filtered through a 0.45‑µm membrane, concentrated to one‑third volume, and treated with 2.05 equivalents of concentrated hydrochloric acid in isopropanol to precipitate (R)-pramipexole dihydrochloride, which is recrystallised from ethanol/water (95:5) to an impurity profile conforming to the United States Pharmacopeia monograph (USP Pramipexole Dihydrochloride RS). The production batch is released against the system suitability test of the Related Compounds procedure, where the (R)-enantiomer peak must elute with a resolution factor Rs ≥ 2.0 from the (S)-enantiomer. Compliance documentation comprises the full audit trail under 21 CFR Part 11 and qualification of the reference standard via inter‑laboratory collaborative trial coordinated with the EDQM OMCL network, yielding a terminal product presented in amber borosilicate vials with a certified chemical purity of 99.7% ± 0.2% (qNMR, internal standard maleic acid) used by quality control units worldwide for batch release of commercial pramipexole tablets.

When a Tetrahydrobenzothiazole‑Based Aminoamide Is Ligated to a Pre‑formed Ruthenium (II) Dimer for Asymmetric Transfer Hydrogenation

A coordination complex generated in situ by stirring 1.0 molar equivalent of (R)-2-Amino-6-propionamido-4,5,6,7-tetrahydrobenzothiazole with 0.5 molar equivalents of bis[(η⁶-p‑cymene)dichlororuthenium(II)] and 2.0 equivalents of potassium hydroxide in anhydrous isopropanol at ambient temperature for 30 minutes yields a chiral catalyst capable of reducing prochiral aryl alkyl ketones to secondary alcohols with enantiomeric ratios exceeding 95:5 at substrate‑to‑catalyst molar ratios up to 5000. The amido‑amino bidentate motif deprotonates to form a five‑membered chelate ring that forces a well‑defined λ‑skewed boat conformation in the tetrahydrobenzothiazole scaffold, as verified by single‑crystal X‑ray diffraction of a model complex deposited with the Cambridge Crystallographic Data Centre. Kinetic profiling under 0.5 MPa hydrogen pressure in a Premex autoclave equipped with a gas‑uptake transducer reveals saturation behaviour above 60 °C; therefore, the validated process window is fixed at 55–58 °C, with pressure maintained at 0.45–0.50 MPa through a cascaded pressure‑reduction valve assembly rated per ISO 4126‑1. The turnover frequency at 40% conversion reaches 1800 h⁻¹ for 4‑chloroacetophenone, and the reaction is terminated by rapid cooling to 10 °C followed by filtration through a pad of acidic alumina to scavenge ruthenium residues below the 10 µg/g threshold mandated for API later‑stage intermediates by ICH Q3D elemental impurity guidance. The liberated (R)-1‑(4‑chlorophenyl)ethanol is purified by short‑path distillation at 0.05 mbar and blended into commercial downstream fractions serving as key chiral intermediates for agrochemicals (azole‑class fungicide side‑chains) and selective serotonin reuptake inhibitor candidates, with each lot accompanied by an audit‑ready process residual solvents report compliant with EMA/CHMP/ICH/82260/2006. The manufacturing facility maintains ISO 14001:2015 certification for spent catalyst recovery through third‑party noble metal smelting loops, ensuring mass balance of ruthenium across the campaign.

Formulation of a photoresponsive cholesteric liquid crystal mesogen wherein the target (R)-aminobenzothiazole unit acts as a covalently bound chiral dopant exhibits a helical twisting power (β) of 22.3 µm⁻¹ in a commercially sourced E7 nematic host, measured by the Cano‑wedge method under λ = 589 nm sodium‑D illumination. The dopant is synthesized by acylating the primary amine with 4‑(6‑acryloyloxyhexyloxy)benzoic acid (1.05 equivalents, EDCI/DMAP coupling in tetrahydrofuran), and the resulting mesogenic monomer is incorporated at 1.8–2.2 wt% into a UV‑curable matrix comprising a difunctional acrylate reactive mesogen blend. The mixture is drawn into 10 µm gap polyimide‑coated cells by capillary action under vacuum and photopolymerised with a 365 nm LED array at 2.5 mW/cm² for 120 seconds, delivering a defect‑free grandjean texture verified by polarising optical microscopy. The selective reflection wavelength can be thermally tuned from 470 nm to 610 nm, a property exploited in thermochromic security labels and anti‑counterfeit window laminates that must satisfy the accelerated weathering protocols of ASTM G154 Cycle 1 (340 nm UVA, black panel 60 °C). End‑use qualification by the convertor requires batch‑specific certificates reporting gel content (solvent extraction in boiling tetrahydrofuran) above 93% and dynamic mechanical analysis glass transition temperature within ±2 °C of the reference lot, ensuring consistent optical texture fidelity when embossed on polyethylene terephthalate carrier film under roll‑to‑roll processing at 15 m/min.